VALN - Valneva Pharma Forward P/S Multiple

Public company logo of Valneva (VALN)

Unique vaccine patents and stringent FDA oversight create a powerful defensive barrier for Valneva SE. The future P/S multiple visualizes this potential, with the current level sitting around 3.30. However, cash flow volatility stemming from government contracts creates risks that are offset by high geopolitical resilience and support from Western governments.

VALN Valneva: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 11/13/2026

VALN (Valneva Vaccines): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Valneva|VALN - Price Target Chart
- market capitalization statistics:
Market Capitalization Valneva Vaccines|VALN - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Valneva|VALN - Company Book Value|Market Value to Book Value Ratio valneva.com|VALN - Total Business Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Valneva SE|VALN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Valneva SE|VALN - Company Debts|Debts to Book Capitalization Valneva Vaccines|VALN - Company Long-Term Debts|Company Current Liabilities Valneva|Quick Liquidity valneva.com
- business earnings and investment ratios data:
VALN - Net Financial Result|Projected Future Earnings Valneva SE|VALN - Market Cap to Earnings|Projected Price to Earnings Valneva Pharma|VALN - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Valneva Vaccines|VALN - Operating profit EBITDA|Earnings per share for the last twelve months Valneva|VALN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months valneva.com|VALN - Earnings per share growth this year|Net earnings per share growth forecast for next year Valneva SE
- sales revenue and business income indicators:
VALN - Company Annual Revenue|Projected Sales Volume Valneva|VALN - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Valneva Vaccines
Summary company analytics:Valneva VALN
Product sample of valneva.com

When screening the reliability of Valneva SE (VALN), investors evaluate the ratio of market value to projected sales. This metric compares current market capitalization with expected turnover to identify any overpayment for future earnings. For this vaccine developer, the calculation accounts for environmental safety costs of production facilities and biohazardous waste disposal. The trend of the future P/S multiple on the GURU.Markets platform helps determine the risk of asset impairment.

Competitors of Valneva SE

Gilead Sciences - Forward Price-to-Revenue Multiple|Cidara Therapeutics Corp - Price-to-Projected Revenue Ratio|Novavax Corp - Forward P/S Multiple|CVAC - Forward P/S Multiple|Vir Biotechnology, Inc. (VIR) - Price-to-Projected Revenue Ratio|SIGA (siga.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Emergent BioSolutions Inc.|Market Cap to Projected Revenue AVIR (Atea Pharma)|Forward P/S Multiple IVVD|ENTA - Market Cap to Future Revenue Ratio|Inovio Pharmaceuticals - Forward Price-to-Revenue Multiple|hillevax.com - Price-to-Projected Revenue Ratio|Kalaris Therapeutics - Forward P/S Multiple|DYAI - Forward P/S Multiple|NNVC (nanoviricides.com) - Forward Price-to-Revenue Multiple|Talphera Corporation - Forward Price to Sales|Price-to-Projected Revenue Ratio Cocrystal Pharma, Inc.|Traws Therapeutics (TRAW) - Market Cap to Expected Sales Ratio|Forward P/S Multiple DWTX|QLGN - Market Cap to Future Revenue Ratio|AlloVir - Forward Price-to-Revenue Multiple|VBI Vaccines, Inc. - Price-to-Projected Revenue Ratio|Virios - Forward P/S Multiple|VXRT - Forward P/S Multiple